Literature DB >> 33672126

Treatment-Resistant Depression Revisited: A Glimmer of Hope.

Angelos Halaris1, Emilie Sohl1, Elizabeth A Whitham1.   

Abstract

Major Depressive Disorder (MDD) is a highly prevalent psychiatric disorder worldwide. It causes individual suffering, loss of productivity, increased health care costs and high suicide risk. Current pharmacologic interventions fail to produce at least partial response to approximately one third of these patients, and remission is obtained in approximately 30% of patients. This is known as Treatment-Resistant Depression (TRD). The burden of TRD exponentially increases the longer it persists, with a higher risk of impaired functional and social functioning, vast losses in quality of life and significant risk of somatic morbidity and suicidality. Different approaches have been suggested and utilized, but the results have not been encouraging. In this review article, we present new approaches to identify and correct potential causes of TRD, thereby reducing its prevalence and with it the overall burden of this disease entity. We will address potential contributory factors to TRD, most of which can be investigated in many laboratories as routine tests. We discuss endocrinological aberrations, notably, hypothalamic-pituitary-adrenal (HPA) axis dysregulation and thyroid and gonadal dysfunction. We address the role of Vitamin D in contributing to depression. Pharmacogenomic testing is being increasingly used to determine Single Nucleotide Polymorphisms in Cytochrome P450, Serotonin Transporter, COMT, folic acid conversion (MTHFR). As the role of immune system dysregulation is being recognized as potentially a major contributory factor to TRD, the measurement of C-reactive protein (CRP) and select immune biomarkers, where testing is available, can guide combination treatments with anti-inflammatory agents (e.g., selective COX-2 inhibitors) reversing treatment resistance. We focus on established and emerging test procedures, potential biomarkers and non-biologic assessments and interventions to apply personalized medicine to effectively manage treatment resistance in general and TRD specifically.

Entities:  

Keywords:  HPA axis; MTHFR; Vitamin D; diabetes; folic acid; major depressive disorder; pharmacogenomics; sex hormones; treatment resistance

Year:  2021        PMID: 33672126     DOI: 10.3390/jpm11020155

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  10 in total

1.  Polymorphisms of COMT and CREB1 are associated with treatment-resistant depression in a Chinese Han population.

Authors:  Yuting Wang; Shen Li; Lichao Niu; Yanyan Ma; Yuying Qiu; Shuhua Li; Nanage Guobule; Haiyan Cao; Jie Li
Journal:  J Neural Transm (Vienna)       Date:  2021-11-12       Impact factor: 3.575

2.  Abnormal expression profile of plasma-derived exosomal microRNAs in patients with treatment-resistant depression.

Authors:  Lian-Di Li; Muhammad Naveed; Zi-Wei Du; Huachen Ding; Kai Gu; Lu-Lu Wei; Ya-Ping Zhou; Fan Meng; Chun Wang; Feng Han; Qi-Gang Zhou; Jing Zhang
Journal:  Hum Genomics       Date:  2021-08-21       Impact factor: 4.639

3.  Effects of Modified Electroconvulsive Therapy on Serum Cortisol, Nesfatin-1, and Pro-inflammatory Cytokine Levels in Elderly Patients With Treatment-Resistant Depression.

Authors:  Biao Dai; Xiaoping Wu; Fanfan Yan; Yang Chen; Yayun Xu; Qingrong Xia; Xulai Zhang; Xuefeng Xie
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

4.  Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial.

Authors:  Helene M Altmann; Joseph Kazan; Marie Anne Gebara; Daniel M Blumberger; Jordan F Karp; Eric J Lenze; Benoit H Mulsant; Charles F Reynolds; Sarah T Stahl
Journal:  Am J Geriatr Psychiatry       Date:  2022-03-10       Impact factor: 7.996

5.  Clinical and Biological Factors Are Associated with Treatment-Resistant Depression.

Authors:  Massimiliano Buoli; Enrico Capuzzi; Alice Caldiroli; Alessandro Ceresa; Cecilia Maria Esposito; Cristina Posio; Anna Maria Auxilia; Martina Capellazzi; Ilaria Tagliabue; Teresa Surace; Francesca Legnani; Luisa Cirella; Martina Di Paolo; Guido Nosari; Francesco Zanelli Quarantini; Massimo Clerici; Fabrizia Colmegna; Antonios Dakanalis
Journal:  Behav Sci (Basel)       Date:  2022-02-03

6.  Frequency of Vitamin D Deficiency in Patients of Asthma.

Authors:  Souhaib Alvi; Jabbar Ghufran Syed; Baakh Nusrat; Syed Kumail Abbas Razvi; Zunaira Z Shah; Yusra Shafaat Khan; Muhammad Danish Khan; Muhammad Ali Khan
Journal:  Cureus       Date:  2021-05-03

7.  Treatment-Resistant Depression in Poland-Epidemiology and Treatment.

Authors:  Piotr Gałecki; Jerzy Samochowiec; Magdalena Mikułowska; Agata Szulc
Journal:  J Clin Med       Date:  2022-01-18       Impact factor: 4.241

8.  Is the JAK-STAT Signaling Pathway Involved in the Pathogenesis of Depression?

Authors:  Małgorzata Gałecka; Janusz Szemraj; Kuan-Pin Su; Angelos Halaris; Michael Maes; Aleksandra Skiba; Piotr Gałecki; Katarzyna Bliźniewska-Kowalska
Journal:  J Clin Med       Date:  2022-04-06       Impact factor: 4.241

9.  Treatment-Resistant Depression in Portugal: Perspective From Psychiatry Experts.

Authors:  João M Bessa; Serafim Carvalho; Inês B Cunha; Milene Fernandes; Ana Matos-Pires; Rui Neves; Albino J Oliveira-Maia; Susana Santos; Vítor Santos
Journal:  Front Psychiatry       Date:  2022-03-30       Impact factor: 4.157

10.  Expression of p11 in Patients with Depression.

Authors:  Małgorzata Gałecka; Katarzyna Bliźniewska-Kowalska; Piotr Gałecki; Janusz Szemraj; Agata Orzechowska
Journal:  J Clin Med       Date:  2022-09-28       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.